抗真菌葡糖神经酰胺单克隆抗体可保护小鼠免受新型隐球菌致死性感染。
Monoclonal antibody to fungal glucosylceramide protects mice against lethal Cryptococcus neoformans infection.
作者信息
Rodrigues Marcio L, Shi Li, Barreto-Bergter Eliana, Nimrichter Leonardo, Farias Sandra E, Rodrigues Elaine G, Travassos Luiz R, Nosanchuk Joshua D
机构信息
Instituto de Microbiologia Professor Paulo de Góes, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-590, Brazil.
出版信息
Clin Vaccine Immunol. 2007 Oct;14(10):1372-6. doi: 10.1128/CVI.00202-07. Epub 2007 Aug 22.
Abstract
Glucosylceramides (GlcCer) are involved in the regulation of Cryptococcus neoformans virulence. In the present study, we demonstrate that passive immunization with a monoclonal antibody to GlcCer significantly reduces host inflammation and prolongs the survival of mice lethally infected with C. neoformans, revealing a potential therapeutic strategy to control cryptococcosis.
摘要
葡糖神经酰胺（GlcCer）参与新型隐球菌毒力的调控。在本研究中，我们证明用针对GlcCer的单克隆抗体进行被动免疫可显著减轻宿主炎症，并延长感染新型隐球菌致死的小鼠的存活时间，揭示了一种控制隐球菌病的潜在治疗策略。
相似文献
1
Monoclonal antibody to fungal glucosylceramide protects mice against lethal Cryptococcus neoformans infection.抗真菌葡糖神经酰胺单克隆抗体可保护小鼠免受新型隐球菌致死性感染。
Clin Vaccine Immunol. 2007 Oct;14(10):1372-6. doi: 10.1128/CVI.00202-07. Epub 2007 Aug 22.
2
Both Th1 and Th2 cytokines affect the ability of monoclonal antibodies to protect mice against Cryptococcus neoformans.Th1和Th2细胞因子均会影响单克隆抗体保护小鼠抵御新型隐球菌的能力。
Infect Immun. 2001 Oct;69(10):6445-55. doi: 10.1128/IAI.69.10.6445-6455.2001.
3
Protection of mice against experimental cryptococcosis by anti-Cryptococcus neoformans monoclonal antibody.抗新型隐球菌单克隆抗体对小鼠实验性隐球菌病的保护作用。
Infect Immun. 1987 Mar;55(3):749-52. doi: 10.1128/iai.55.3.749-752.1987.
4
Glucosylceramide Administration as a Vaccination Strategy in Mouse Models of Cryptococcosis.在隐球菌病小鼠模型中，将葡萄糖神经酰胺作为一种疫苗接种策略进行给药。
PLoS One. 2016 Apr 15;11(4):e0153853. doi: 10.1371/journal.pone.0153853. eCollection 2016.
5
Cryptococcus neoformans infection can elicit protective antibodies in mice.新型隐球菌感染可在小鼠体内引发保护性抗体。
Can J Microbiol. 1994 Oct;40(10):888-92. doi: 10.1139/m94-141.
6
Immunoglobulin M efficacy against Cryptococcus neoformans: mechanism, dose dependence, and prozone-like effects in passive protection experiments.免疫球蛋白M对新型隐球菌的疗效：被动保护实验中的作用机制、剂量依赖性及前带样效应
J Immunol. 2001 Feb 1;166(3):2100-7. doi: 10.4049/jimmunol.166.3.2100.
7
Passive immunization in murine cryptococcosis.小鼠隐球菌病中的被动免疫
Sabouraudia. 1981 Dec;19(4):237-44. doi: 10.1080/00362178185380411.
8
Protective and nonprotective human immunoglobulin M monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan manifest different specificities and gene use profiles.针对新型隐球菌葡糖醛酸木聚糖甘露聚糖的保护性和非保护性人免疫球蛋白M单克隆抗体表现出不同的特异性和基因使用谱。
Infect Immun. 2004 Aug;72(8):4810-8. doi: 10.1128/IAI.72.8.4810-4818.2004.
9
A cryptococcal capsular polysaccharide mimotope prolongs the survival of mice with Cryptococcus neoformans infection.一种新型隐球菌感染小鼠的隐球菌荚膜多糖模拟表位可延长其生存期。
J Immunol. 2001 Jan 15;166(2):1087-96. doi: 10.4049/jimmunol.166.2.1087.
10
Mechanism for the isotype dependence of antibody-mediated toxicity in Cryptococcus neoformans-infected mice.新型隐球菌感染小鼠中抗体介导毒性的同种型依赖性机制。
J Immunol. 2000 Apr 15;164(8):4367-74. doi: 10.4049/jimmunol.164.8.4367.
引用本文的文献
1
Trimming the fat: a brief review of lipids at the host-pathogen interface.去除脂肪：宿主-病原体界面脂质的简要综述
Infect Immun. 2025 Jul 8;93(7):e0050624. doi: 10.1128/iai.00506-24. Epub 2025 Jun 13.
2
The antimicrobial activity of ETD151 defensin is dictated by the presence of glycosphingolipids in the targeted organisms.ETD151防御素的抗菌活性取决于靶标生物中糖鞘脂的存在。
Proc Natl Acad Sci U S A. 2025 Feb 18;122(7):e2415524122. doi: 10.1073/pnas.2415524122. Epub 2025 Feb 12.
3
Will the Real Immunogens Please Stand Up: Exploiting the Immunogenic Potential of Cryptococcal Cell Antigens in Fungal Vaccine Development.真正的免疫原请站出来：在真菌疫苗开发中利用隐球菌细胞抗原的免疫原性潜力。
J Fungi (Basel). 2024 Dec 4;10(12):840. doi: 10.3390/jof10120840.
4
Monoclonal antibodies: From magic bullet to precision weapon.单克隆抗体：从“魔弹”到“精准武器”。
Mol Biomed. 2024 Oct 11;5(1):47. doi: 10.1186/s43556-024-00210-1.
5
Role of sphingolipids in the host-pathogen interaction.鞘脂类在宿主-病原体相互作用中的作用。
Biochim Biophys Acta Mol Cell Biol Lipids. 2023 Nov;1868(11):159384. doi: 10.1016/j.bbalip.2023.159384. Epub 2023 Sep 4.
6
Professor Luiz R. Travassos and the study of surface structures of fungal pathogens.Luiz R. Travassos 教授与真菌病原体表面结构的研究。
Braz J Microbiol. 2023 Dec;54(4):2571-2575. doi: 10.1007/s42770-023-00916-4. Epub 2023 Feb 1.
7
Harnessing the Immune Response to Fungal Pathogens for Vaccine Development.利用免疫应答开发针对真菌病原体的疫苗
Annu Rev Microbiol. 2022 Sep 8;76:703-726. doi: 10.1146/annurev-micro-041020-111511. Epub 2022 Jun 27.
8
Development and Application of Rapid Clinical Visualization Molecular Diagnostic Technology for / Based on Recombinase Polymerase Amplification Combined With a Lateral Flow Strip.基于重组酶聚合酶扩增联合侧向流层析技术的快速临床可视化分子诊断技术的建立与应用。
Front Cell Infect Microbiol. 2022 Jan 12;11:803798. doi: 10.3389/fcimb.2021.803798. eCollection 2021.
9
Drug Resistance and Novel Therapeutic Approaches in Invasive Candidiasis.侵袭性念珠菌病的耐药性及新的治疗方法。
Front Cell Infect Microbiol. 2021 Dec 14;11:759408. doi: 10.3389/fcimb.2021.759408. eCollection 2021.
10
Monoclonal Antibodies against Cell Wall Chitooligomers as Accessory Tools for the Control of Cryptococcosis.针对细胞壁几丁寡糖的单克隆抗体作为控制隐球菌病的辅助工具。
Antimicrob Agents Chemother. 2021 Nov 17;65(12):e0118121. doi: 10.1128/AAC.01181-21. Epub 2021 Sep 27.
本文引用的文献
1
An anti-beta-glucan monoclonal antibody inhibits growth and capsule formation of Cryptococcus neoformans in vitro and exerts therapeutic, anticryptococcal activity in vivo.一种抗β-葡聚糖单克隆抗体在体外可抑制新型隐球菌的生长和荚膜形成，并在体内发挥治疗性抗隐球菌活性。
Infect Immun. 2007 Nov;75(11):5085-94. doi: 10.1128/IAI.00278-07. Epub 2007 Jul 2.
2
Vesicular polysaccharide export in Cryptococcus neoformans is a eukaryotic solution to the problem of fungal trans-cell wall transport.新型隐球菌中的囊泡多糖输出是真菌跨细胞壁运输问题的一种真核解决方案。
Eukaryot Cell. 2007 Jan;6(1):48-59. doi: 10.1128/EC.00318-06. Epub 2006 Nov 17.
3
Cryptococcosis.隐球菌病
Infect Dis Clin North Am. 2006 Sep;20(3):507-44, v-vi. doi: 10.1016/j.idc.2006.07.001.
4
Role of capsule and interleukin-6 in long-term immune control of Cryptococcus neoformans infection by specifically activated human peripheral blood mononuclear cells.荚膜和白细胞介素-6在特异性激活的人外周血单个核细胞对新型隐球菌感染的长期免疫控制中的作用。
Infect Immun. 2006 Sep;74(9):5302-10. doi: 10.1128/IAI.00661-06.
5
Glucosylceramide synthase is an essential regulator of pathogenicity of Cryptococcus neoformans.葡糖神经酰胺合酶是新型隐球菌致病性的重要调节因子。
J Clin Invest. 2006 Jun;116(6):1651-9. doi: 10.1172/JCI27890.
6
Cryptococcal virulence: beyond the usual suspects.隐球菌毒力：超越常见因素
J Clin Invest. 2006 Jun;116(6):1481-3. doi: 10.1172/JCI28842.
7
Structure, cellular distribution, antigenicity, and biological functions of Fonsecaea pedrosoi ceramide monohexosides.裴氏瓶霉神经酰胺单己糖苷的结构、细胞分布、抗原性及生物学功能
Infect Immun. 2005 Dec;73(12):7860-8. doi: 10.1128/IAI.73.12.7860-7868.2005.
8
Monoclonal immunoglobulin G1 directed against Aspergillus fumigatus cell wall glycoprotein protects against experimental murine aspergillosis.针对烟曲霉细胞壁糖蛋白的单克隆免疫球蛋白G1可预防实验性小鼠曲霉病。
Clin Diagn Lab Immunol. 2005 Sep;12(9):1063-8. doi: 10.1128/CDLI.12.9.1063-1068.2005.
9
Cryptococcal meningitis.隐球菌性脑膜炎
Br Med Bull. 2005 Apr 18;72:99-118. doi: 10.1093/bmb/ldh043. Print 2004.
10
The multitude of targets for the immune system and drug therapy in the fungal cell wall.真菌细胞壁中免疫系统和药物治疗的众多靶点。
Microbes Infect. 2005 Apr;7(4):789-98. doi: 10.1016/j.micinf.2005.03.002. Epub 2005 Mar 17.
Zotero 插件